The therapeutic potential of resveratrol: a review of clinical trials
- PMID: 28989978
- PMCID: PMC5630227
- DOI: 10.1038/s41698-017-0038-6
The therapeutic potential of resveratrol: a review of clinical trials
Abstract
Resveratrol is a nutraceutical with several therapeutic effects. It has been shown to mimic effects of caloric restriction, exert anti-inflammatory and anti-oxidative effects, and affect the initiation and progression of many diseases through several mechanisms. While there is a wealth of in vitro and in vivo evidence that resveratrol could be a promising therapeutic agent, clinical trials must confirm its potential. In this work, we reviewed the current clinical data available regarding the pharmacological action of resveratrol. Most of the clinical trials of resveratrol have focused on cancer, neurological disorders, cardiovascular diseases, diabetes, non-alcoholic fatty liver disease (NAFLD), and obesity. We found that for neurological disorders, cardiovascular diseases, and diabetes, the current clinical trials show that resveratrol was well tolerated and beneficially influenced disease biomarkers. However resveratrol had ambiguous and sometimes even detrimental effects in certain types of cancers and in NAFLD. In most of the clinical trials, the major obstacle presented was resveratrol's poor bioavailability. Thus, this work provides useful considerations for the planning and design of future pre-clinical and clinical research on resveratrol.
Conflict of interest statement
The authors declare that they have no competing financial interests.
Figures
Similar articles
-
Current Update on Preclinical and Clinical Studies of Resveratrol, a Naturally Occurring Phenolic Compound.Crit Rev Eukaryot Gene Expr. 2019;29(6):529-537. doi: 10.1615/CritRevEukaryotGeneExpr.2019027836. Crit Rev Eukaryot Gene Expr. 2019. PMID: 32422008 Review.
-
Resveratrol: from enhanced biosynthesis and bioavailability to multi_targeting chronic diseases.Biomed Pharmacother. 2019 Jan;109:2237-2251. doi: 10.1016/j.biopha.2018.11.075. Epub 2018 Nov 28. Biomed Pharmacother. 2019. PMID: 30551481 Review.
-
Resveratrol and health--a comprehensive review of human clinical trials.Mol Nutr Food Res. 2011 Aug;55(8):1129-41. doi: 10.1002/mnfr.201100143. Epub 2011 Jun 20. Mol Nutr Food Res. 2011. PMID: 21688389 Review.
-
Mitochondrial biogenesis: pharmacological approaches.Curr Pharm Des. 2014;20(35):5507-9. doi: 10.2174/138161282035140911142118. Curr Pharm Des. 2014. PMID: 24606795
-
Resveratrol's Potential in the Adjunctive Management of Cardiovascular Disease, Obesity, Diabetes, Alzheimer Disease, and Cancer.J Am Osteopath Assoc. 2018 Sep 1;118(9):596-605. doi: 10.7556/jaoa.2018.133. J Am Osteopath Assoc. 2018. PMID: 30178049 Review.
Cited by
-
Resveratrol's bibliometric and visual analysis from 2014 to 2023.Front Plant Sci. 2024 Oct 8;15:1423323. doi: 10.3389/fpls.2024.1423323. eCollection 2024. Front Plant Sci. 2024. PMID: 39439517 Free PMC article.
-
The Effect of Resveratrol on Blood Lipid Profile: A Dose-Response Meta-Analysis of Randomized Controlled Trials.Nutrients. 2022 Sep 11;14(18):3755. doi: 10.3390/nu14183755. Nutrients. 2022. PMID: 36145131 Free PMC article. Review.
-
Resveratrol as an Anti-inflammatory Agent in Coronary Artery Disease: A Systematic Review, Meta-Analysis and Meta-Regression.Chin J Integr Med. 2024 Oct;30(10):927-937. doi: 10.1007/s11655-024-3665-0. Epub 2024 Jul 3. Chin J Integr Med. 2024. PMID: 38958883
-
Resveratrol: A potential therapeutic natural polyphenol for neurodegenerative diseases associated with mitochondrial dysfunction.Front Pharmacol. 2022 Sep 16;13:922232. doi: 10.3389/fphar.2022.922232. eCollection 2022. Front Pharmacol. 2022. PMID: 36188541 Free PMC article. Review.
-
An innovative biotransformation to produce resveratrol by Bacillus safensis.RSC Adv. 2019 May 17;9(27):15448-15456. doi: 10.1039/c9ra01338e. eCollection 2019 May 14. RSC Adv. 2019. PMID: 35514846 Free PMC article.
References
-
- Aggarwal BB, et al. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24:2783–2840. - PubMed
-
- Bavaresco L, P. D, Cantu E, et al. Elicitation and accumulation of stilbene phytoalexins in grapevine berries infected by Botrytis cinerea. Vitis. 1997;36:77–83.
-
- Langcake PWVM. The relationship of resveratrol production to infection of grapevine leaves by Botrytis cinerea. Vitis. 1979;18:244–253.
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources